Finding great science and building promising startups to deliver better medicines for patients.

Novel therapeutics for advanced liver diseases
alentis.ch

BMI responsible: Mr. Thomas Möller

ALENTIS Therapeutics, based in Basel (CH) and Strasbourg (F), is a spin-out of the University of Strasbourg developing novel therapeutics for advanced liver disease and cancer.

Novel treatments for multi drug-resistant bacterial infections
www.allecra.com

BMI responsible: Hr. Thomas Möller

Allecra therapeutics is based in the European BioValley Life Sciences cluster located in the Upper Rhine valley (D, F and CH) and is focused on the development of novel treatments to combat multi drug-resistant Gram-negative bacterial infections.

New treatment options for rare metabolic diseases
www.azafaros.com

BMI responsible: Dr. Kiran Dallenbach

Azafaros is a Basel-based company addressing rare lysosomal storage diseases through a pipeline of oral small molecules with disease-modifying potential.

Novel human immunomodulatory proteins for cancer treatment
www.immunostherapeutics.com

BMI responsible: Dr. Markus Hosang & Dr. Kiran Dallenbach

ImmunOs Therapeutics, a spin-off of the University of Zurich and University of Basel (CH), is leading the discovery and development of the next generation of novel human immunomodulatory proteins involving the innate immune system for cancer treatments that not only have direct anti-tumor effects but also remodel the tumor microenvironment and enhance the efficacy of existing immunotherapies.

www.noemapharma.com

BMI responsible: Dr. Valentin Piëch

Noema Pharma is a Swiss-based company targeting orphan neurological disorders characterized by imbalanced neuronal networks. The company is developing four mid-clinical-stage therapeutic products in-licensed from Roche and with strong safety packages. Lead product NOE-101, an mGluR5 inhibitor, is Phase 2b-ready for two indications: persistent seizures in Tuberous Sclerosis Complex (TSC) and severe pain in Trigeminal Neuralgia (TN). NOE-105, a PDE10A inhibitor, is in preparation for Phase 2b testing to treat Tourette Syndrome. The Company is undertaking validation studies in undisclosed indications for two additional clinical-stage assets, NOE-109, an mGluR2/3 inhibitor, and NOE-115, a triple re-uptake inhibitor.

Radio-immunotherapeutic drugs for cancer patients
www.precirix.com

BMI responsible: Dr. Michael Wacker

PRECIRIX is a spin-off from VUB (Vrije Universiteit Brussel, Belgium), developing new radiopharmaceuticals based on linking single domain antibody fragments with radioisotopes to treat cancer.

Genetic modifiers for cancer and rare diseases
www.scenicbiotech.com

BMI responsible: Dr. Michael Wacker

Scenic Biotech B.V. is a spin-out of the Netherlands Cancer Institute and Oxford University, applying its Cell-Seq platform technology to progress a pipeline of genetic modifiers in cancer and rare diseases.

Preventing resistance to cancer therapy
www.tolremo.com

BMI responsible: Dr. Michael Wacker

TOLREMO Therapeutics AG is a spin-off from ETH Zurich (CH) targeting novel mechanisms to prevent resistance development to cancer therapies.

www.topas-therapeutics.com

BMI responsible: Dr. Michael Wacker

Topas Therapeutics GmbH is a privately held German biotech company with lab facilities in Hamburg, Germany. Topas Therapeutics is currently performing a Phase I studies in Pemphigus Vulgaris (PV) patients, an autoimmune disease attacking the human skin. Topas pursues a unique approach in tolerization of the immune system against known antigens using a patented therapeutic concept for peptide‐nanoparticle‐formulation. The fundamental biology of Topas approach is that the liver provides a tolerogenic environment and presented antigens (including auto‐antigens, delivered to appropriate sinusoidal cells in the liver) will elicit a tolerogenic response as opposed to an immunogenic response.